


CERTIFICATE OF MAILING

I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 17th day of March, 2003.

Type or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy A. Frick



24024

PATENT TRADEMARK OFFICE

RECEIVED

MAR 26 2003

TECH CENTER 1600/2900

1658
P#9

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kaumaya, et al.

Serial No.: 09/990,574

Filed: November 21, 2001

For: **AGENTS FOR BLOCKING T CELL
MEDIATED IMMUNE REACTIONS**

) Examiner: Not yet assigned

) Art Unit: 1653

) Attorney Docket No.: 18525/04028

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith are the following:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. 4 References; and
4. A Return Receipt Postcard.


It is believed that no further fee is required relating to the filing of this Information Disclosure Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: March 17, 2003

By: Pamela A. Docherty

Pamela A. Docherty, Reg. No. 40,591
(216) 622-8416



CERTIFICATE OF MAILING



24024

PATENT TRADEMARK OFFICE

I hereby certify that this INFORMATION DISCLOSURE STATEMENT is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 17th day of March, 2003.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed:

Wendy A. Frick

RECEIVED

MAR 26 2003

TECH CENTER 1600/2300

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kaumaya, et al.

Serial No.: 09/990,574

Filed: November 21, 2001

For: **AGENTS FOR BLOCKING T CELL
MEDIATED IMMUNE REACTIONS**

Examiner: Not yet assigned

Art Unit: 1653

Attorney Docket No.: 18525/04028

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The information enclosed and cited on the accompanying form PTO-1449 is hereby submitted in compliance with 37 CFR §§1.56, 1.97 and 1.98 for consideration by the Examiner in connection with the application.

Respectfully submitted,

Date:

March 17, 2003

By:

Pamela A. Docherty
Pamela A. Docherty, Reg. No. 40,591
(216) 622-8416



Subst. Form PTO 1049 APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 18525/04028	Serial No.: 09/990,574
Applicant: Kaumaya, et al.		JTECH CENTER 1600/2900
Filing Date: November 21, 2001		
		Group: 1653

U.S. PATENT DOCUMENTS

Initial*	Document No.	Date	Name	Class	Subcl.	Filing Date
AA						
AB						
AC						
AD						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE						
AF						
AG						
AH						
AI						

OTHER PRIOR ART

AJ	"Costimulatory Blockade by CD28 Peptide Mimics: Suppression of Experimental Autoimmune Encephalomyelitis" by Srinivasan, et al., <u>American Peptide Society</u> , June 9, 2001, pp. 654-655.
AK	"A CD28 CDR3 peptide analog inhibits CD4+ T-cell proliferation <i>in vitro</i> " by Srinivasan, et al., <u>Peptides for the New Millenium</u> (Eds. Fields, G.B., Tam T.P. and Barany) Kluwer Academic Publishers, Dordrecht, Netherlands, June 26, 1999, pp. 689-690.
AL	"A Retro-Inverso Peptide Mimic of CD28 Encompassing the MYPPPY Motif Adopts a Polyproline Type II Helix and Inhibits Encephalitogenic T Cells In Vitro" by Srinivasan, <u>The Journal of Immunology</u> , Vol. 167(1), July 1, 2001, pp. 578-585.
AM	"Suppression of Experimental Autoimmune Encephalomyelitis Using Peptide Mimics of CD28" by Srinivasan, et al., <u>The Journal of Immunology</u> , 2002, 169: 2180-2188.
AN	
AO	
AP	
AQ	
AR	
Examiner:	
Date Considered:	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.